Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P500

Evolution after anti-TNF drug discontinuation in patients with inflammatory bowel disease (IBD): a multicenter long-term follow-up study.

Authors:

M.J. Casanova*1, M. Chaparro1, V. García-Sánchez2, O. Nantes3, A. Jáuregui-Amezaga4, M. Rojas-Feria5, J.R. Pineda6, J. Tosca7, M.P. Martínez-Montiel8, L. Luzón9, R. Pajares10, B. Beltrán11, M. Barreiro de-Acosta12, L. Ramos13, I. Pérez-Martínez14, F. Bermejo15, Y. González-Lama16, M. Domínguez-Cajal17, J.M. Huguet18, B. Sicilia19, C. Dueñas-Sadornil20, A. Ponferrada-Díaz21, O. Merino22, X. Calvet23, M. Menacho24, J. Guardiola25, P. Ramírez de la Piscina26, J.L. Pérez-Calle27, M. Domínguez-Antonaya28, M. Piqueras29, L. Fernández-Salazar30, D. Busquets31, J.M. Benítez-Cantero2, C. Rodriguez3, J.P. Gisbert1

1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, 2Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain, 3Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain, 4Hospital Clinic de Barcelona and CIBERehd, Gastroenterology Unit, Barcelona, Spain, 5Hospital de Valme and CIBERehd, Gastroenterology Unit, Sevilla, Spain, 6Complejo Hospitalario Universitario de Vigo, Gastroenterology Unit, Vigo, Spain, 7Hospital Clínico Universitario, Gastroenterology Unit, Valencia, Spain, 8Hospital Universitario 12 de Octubre, Gastroenterology Unit, Madrid, Spain, 9Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain, 10Hospital Infanta Sofía, Gastroenterology Unit, Madrid, Spain, 11Hospital Universitario La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, 12Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, 13Hospital Universitario de Canarias, Gastroenterology Unit, SantaCruz de Tenerife, Spain, 14Hospital Universitario Central de Asturias, Gastroenterology Unit, Oviedo, Spain, 15Hospital Universitario de Fuenlabrada, Gastroenterology Unit, Madrid, Spain, 16Hospital Puerta de Hierro, Gastroenterology Unit, Madrid, Spain, 17Hospital General San Jorge, Gastroenterology Unit, Huesca, Spain, 18Consorcio Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain, 19Hospital Universitario de Burgos, Gastroenterology unit, Burgos, Spain, 20Hospital San Pedro de Alcántara, Gastroenterology Unit, Cáceres, Spain, 21Hospital Infanta Leonor, Gastroenterology Unit, Madrid, Spain, 22Hospital Universitario de Cruces, Gastroenterology Unit, Bilbao, Spain, 23Hospital de Sabadell. Corporació Sanitària Universitària Parc Taulí and CIBERehd, Gastroenterology Unit, Sabadell, Spain, 24Hospital Joan XXIII, Gastroenterology Unit, Tarragona, Spain, 25Hospital de Bellvitge, Gastroenterology unit, Barcelona, Spain, 26Hospital Universitario de Alava, Gastroenterology Unit, Vitoria, Spain, 27Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain, 28Hospital Universitario de Móstoles, Gastroenterology Unit, Madrid, Spain, 29Hospital Universitari Mutua de Terrasa, Gastroenterology Unit, Barcelona, Spain, 30Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain, 31Hospital universitari de Girona Dr Josep Trueta, Gastroenterology Unit, Girona, Spain

P501.

Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders

Authors:

B. Feagan1, W.J. Sandborn2,3, M. Smyth4, S. Sankoh5, A. Parikh6, I. Fox7, 1Western University/Robarts Research Institute, Robarts Clinical Trials Inc, London, Ontario, Canada, 2University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 4Takeda Development Centre (Europe) Ltd, General Medicine/GI/Renal, London, United Kingdom, 5Takeda Pharmaceuticals International Company, Global Statistics, Cambridge, United States, 6Takeda Pharmaceuticals International, Inc., General Medicine, Deerfield, United States, 7Takeda Pharmaceuticals International Company, Clinical Development, Cambridge, United States

P501. Fecal calprotectin in monitoring active ulcerative colitis
Authors:

K. Theede1, M. Kiszka-Kanowitz1, I. Nordgaard-Lassen1, 1Copenhagen University Hospital Hvidovre, Gastrounit, Medical Section, Hvidovre, Denmark

P501

Relationship between measures of infliximab exposure and clinical outcome of infliximab intensification at therapeutic failure in Crohn's disease

Authors:

C. Steenholdt*1, H. Edlund2, 3, M.A. Ainsworth1, J. Brynskov1, O.Ø. Thomsen1, W. Huisinga4, C. Kloft2

1Herlev Hospital, Dept of Gastroenterology, Herlev, Denmark, 2Freie Universitaet Berlin, Dept. of Clinical Pharmacy and Biochemistry, Berlin, Germany, 3Freie Universitaet Berlin, Graduate Research Training Program PharMetrX, Berlin, Germany, 4Universitaet Potsdam, Institute of Mathematics, Potsdam, Germany

P502.

Effect of immunosuppressive treatment in the efficacy of Hepatitis B vaccine in patients with inflammatory bowel disease

Authors:

J. Santos-Antunes, P. Andrade, S. Rodrigues, F. Magro, S. Lopes, G. Macedo, Centro Hospitalar São João, Gastroenterology, Porto, Portugal

P502. Feasibility and safety of totally laparoscopic restorative proctocolectomy for ulcerative colitis in the elderly. A prospective cohort study
Authors:

F. Colombo1, G. Sampietro1, F. Alice1, S. Casiraghi1, A. Cassinotti1, S. Ardizzone1, F. Corsi1, D. Foschi1, 1“Luigi Sacco” University Hospital, Surgery, Gastroenterology and Oncology, Milano, Italy

P502

Predictors of bad response to infliximab in Ulcerative Colitis patients (ECIA study. ACAD)

Authors:

L. Fernández-Salazar*1, N. Fernández2, R. Sánchez-Ocaña3, D. Joao2, F. Santos3, A. Bouhmidi4, J. Legido5, V. Prieto6, M. Rivero7, R. Pajares8, C. Muñoz9, M. Herranz10, A. Macho1, J. Barrio3, F. Muñoz2

1Hospital Clínico Universitario, Gastroenterology, Valladolid, Spain, 2Complejo Asistencial Universitario, Gastroenterology, León, Spain, 3Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain, 4Hospital Santa Bárbara de Puertollano, Gastroenterology, Ciudad Real, Spain, 5Complejo Asistencial de Segovia, Gastroenterology, Segovia, Spain, 6Complejo Asistencial Universitario, Gastroenterology, Salamanca, Spain, 7Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain, 8Hospital Infanta Sofía, Gastroenterology, San Sebastián de los Reyes. Madrid, Spain, 9Hospital Virgen de la Salud, Gastroenterology, Toledo, Spain, 10Complejo Asistencial de Ávila, Gastroenterology, Avila, Spain

P503. Fatigue in IBD patients decreases with psychotherapy: results of a randomized controlled trial
Authors:

L. Vogelaar1, A. van 't Spijker2, R. Timman2, A. van Tilburg3, D. Bac4, E.J. Kuipers5, J.J. van Busschbach2, C.J. van der Woude5, 1Erasmus Medical Center, Department of Gastroenterology & Hepatology, Rotterdam, Netherlands, 2ErasmusMC, Department of Psychology and Psychotherapy, Rotterdam, Netherlands, 3Sint Franciscus Gasthuis, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 4Gelderse Vallei, Department of Gastroenterology and Hepatology, Ede, Netherlands, 5ErasmusMC, Gastroenterology and Hepatology, Rotterdam, Netherlands

P503

Infliximab and adalimumab serum levels predict probability of mucosal healing

Authors:

B. Ungar*1, I. Levy1, Y. Yavne1, M. Yavzori1, E. Fudim1, O. Picard1, R. Loebstein2, U. Kopylov1, Y. Chowers3, R. Eliakim1, S. Ben-Horin1

1Sheba Medical Center & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, 2Sheba Medical Center & Sackler School of Medicine, Institute of Clinical Pharmacology, Tel Hashomer, Israel, 3Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel

P504.

Effectiveness and adverse events of azathioprine in inflammatory bowel disease: 9-year follow-up study

Authors:

I. Guerra1, A. Algaba1, Á. Serrano2, C. Aulló3, D. Alcalde1, M. de Lucas1, D. Bonillo1, A. Zapatero4, F. Bermejo1, 1Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain, 2Hospital Universitario de Fuenlabrada, Surgery, Madrid, Spain, 3Hospital Universitario de Fuenlabrada, Radiology, Madrid, Spain, 4Hospital Universitario de Fuenlabrada, Internal Medicine, Madrid, Spain

P504. Familial aggregation in the response to anti-TNF in inflammatory bowel disease patients
Authors:

T. Billiet1, I. Cleynen2, V. Ballet2, M. Ferrante2, K. Van Steen3, P. Rutgeerts2, S. Vermeire2, 1KU Leuven, IBD Group, Leuven, Belgium, 2KU Leuven, IBD Group, Belgium, 3ULG, Montefiore Institute / Bioinformatics – Statistical Genetics, Belgium

P504

Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons

Authors:

D. Wolf*1, M. Skup2, H. Yang3, E. Faust3, A. Kageleiry3, J. Chao2, M. Lebwohl4

1Atlanta Gastroenterology Associates, , Atlanta, GA, United States, 2AbbVie Inc., Global Health Economics & Outcomes Research, North Chicago, United States, 3Analysis Group, Inc., , Boston, MA, United States, 4Icahn School of Medicine at Mount Sinai, Medicine, New York, United States

P505.

ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies – Preliminary data

Authors:

G. Bodini1, V. Savarino1,2, P. Dulbecco1,2, I. Baldissarro1,2, E. Savarino1,3,4, 1IRCCS San Martino Genova, Dipartimento di medicina interna, Genova, Italy, 2Università di Genova, Dipartimento di Medicina Interna, Genova, Italy, 3University of Padua, Department of Surgery, Oncology and Gastroenterology, padova, Italy, 4Department of Surgery, Oncology and Gastroenterology, University of Padua, gastroenteroly unit, padua, Italy

P505. Factors influencing adherence to treatment with anti-TNF agents in ulcerative and Crohn's disease patients: a prospective study
Authors:

N. Borruel1, E. Navarro1, V. Robles1, A. Torrejon1, F. Casellas1, 1UACC. Digestive System Reserach Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain

P505

Biosimilar but not the same

Authors:

C. Murphy*, K. Sugrue, G. Mohamad, J. McCarthy, M. Buckley

Mercy University Hospital, University College Cork, Centre for Gastroenterology, Mercy University Hospital, Cork, Ireland

P506.

Efficacy and safety of two bowel preparations for colonoscopy in IBD patients

Authors:

I. Frankovic1, M. Martinato1, C. Mescoli2, R. Caccaro1, A.C. Frigo3, M. Rugge2, G.C. Sturniolo1, R. D'Incà1, 1Padua, Surgical, Gastroenterological and Oncological Sciences, Padua, Italy, 2Padua, Diagnostic, Medical Sciences and Special Therapies, Surgical Pathology and Cytopathology Unit, Padua, Italy, 3Padua, Environmental Medicine and Public Health, Padua, Italy

P506. Follow-up of ulcerative colitis patients after a first course of endovenous corticosteroids
Authors:

A. Hernandez Camba1, N. Hernandez Alvarez-Buylla1, N. Garcia Borges2, I. Alonso1, M. Carrillo1, L. Ramos1, E. Quintero1, 1Hospital Universitario de Canaris, Gastroenterology, La Laguna, Spain, 2Universidad de la Laguna, Facultad de Medicina, La Laguna, Spain

P506

Predictors of Health-related Quality of Life in Asian Patients with Inflammatory Bowel Disease: Psychological, Clinical and Demographic factors

Authors:

X.-p. Luo*, R. Mao, Y. He, B.-l. Chen, Z.-r. Zeng, M.-h. Chen

First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P507.

EBV serology status and azathioprine-associated complications: a single centre study

Authors:

P. Sousa, P. Ministro, D. Martins, E. Cancela, J. Machado, A. Silva, Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal

P507. Evolution of osteopenia and osteoporosis over 5 years in patients with inflammatory bowel disease
Authors:

F. Casals-Seoane1, M. Chaparro1, M.-R. González-Casas1, J. Maté-Jiménez1, J.P. Gisbert1, 1Hospital Universitario de La Princesa, IP, Gastroenterology and CIBEREHD, Madrid, Spain